EBV EliSpot (lytic)

The EBV EliSpot (lytic) detects the number of T-cells in your blood that produce interferon-gamma (IFN-γ) when exposed to lytic-phase Epstein–Barr virus (EBV) antigens—the proteins EBV expresses when it is actively replicating.

• It is a cellular immunity assay (T-cell function), not an antibody (IgG/IgM) test.

• Results are reported as a Stimulation Index (SI), which compares the response to EBV peptides against a negative control.

Reference interpretation (ArminLabs):

• 0–1 SI: Negative

• 2–3 SI: Weak positive

• >3 SI: Positive

In plain language: a higher SI means more EBV-reactive T-cells were detected during the test.

---

Why “lytic” matters

EBV has two major life-cycle states:

• Lytic phase: the virus is replicating and producing new virions (often associated with recent infection or reactivation).

• Latent phase: the virus lies mostly “quiet,” expressing a different set of proteins.

This test targets lytic antigens, so it’s most informative when you’re assessing recent activity or reactivation rather than long-standing latent carriage alone.

---

How to interpret results

Negative (0–1 SI)

• Meaning: No significant EBV-specific T-cell response to lytic antigens was detected.

• Clinical context: In an otherwise healthy person, this lowers the likelihood of current lytic-phase activity. It does not rule out past EBV infection (most adults have been exposed) and does not exclude latency.

• Next steps: If symptoms strongly suggest EBV (fever, sore throat, lymph node swelling, hepatitis-like labs), consider EBV serology (VCA-IgM/IgG, EBNA-1 IgG, EA-IgG) and/or EBV DNA PCR to check for viral replication. Re-test if symptoms persist or evolve.

Weak positive (2–3 SI)

• Meaning: A low-level T-cell response to lytic antigens.

• Clinical context: Could reflect very recent or resolving activity, mild reactivation, or immune memory; interpretation relies heavily on symptoms and other labs.

• Next steps: Correlate clinically. If you’re symptomatic, pair with EBV DNA PCR and a complete EBV serology panel. Recheck in 4–6 weeks to see if the signal is rising or settling.

Positive (>3 SI)

• Meaning: A clear T-cell response to lytic-phase EBV antigens.

• Clinical context: Supports recent infection or reactivation, especially if you have compatible symptoms or supportive serology (e.g., rising EA-IgG or VCA-IgM in acute settings). That said, some individuals maintain strong memory responses even when clinically well—hence the need for context.

• Next steps: If symptomatic, consider EBV DNA PCR (viral load), CBC with differential (look for atypical lymphocytes/lymphocytosis), and liver enzymes (ALT/AST, ALP, bilirubin). Track symptoms and consider repeating the EliSpot and/or PCR in 4–6 weeks.

---

What this test does not show by itself

• It does not provide a viral load (use EBV DNA PCR for that).

• It does not stage infection on its own; pairing with serology clarifies whether infection is acute, recent, reactivated, or past/latent.

• A positive result doesn’t automatically mean disease—many adults have robust EBV memory responses without symptoms.

---

How this complements other EBV tests

• Serology (antibodies):

  • VCA-IgM: often rises in acute infection.

  • VCA-IgG & EBNA-1 IgG: help determine past vs. recent infection.

  • EA-IgG: can rise in acute/reactivation, but may persist in a subset of healthy individuals.

• EBV DNA PCR (blood/plasma): best direct marker of ongoing replication and viral load.

• EliSpot (latent): measures T-cell responses to latent antigens; combining lytic and latent EliSpots can give a broader view of EBV-specific cellular immunity.

---

When clinicians might order this test

• Persistent, mono-like illness (fatigue, sore throat, lymphadenopathy), hepatitis-like enzyme elevations, or prolonged convalescence after suspected EBV.

• Suspected reactivation in contexts such as stress, other infections, or immunomodulatory therapies.

• Complex, multisystem symptoms where EBV activity is part of a differential and cellular immunity insight would add value.

• Monitoring a previously positive case to see if cellular responses are trending down as symptoms resolve (use alongside clinical status and, when appropriate, PCR).

---

Factors that can influence results

• Immune status & medications: Immunosuppression (e.g., high-dose steroids, biologics, chemotherapy) can blunt T-cell responses and yield falsely low SI.

• Acute intercurrent illness: Other infections or systemic inflammation can modulate T-cell reactivity.

• Pre-analytical variables: Delays in processing or improper handling can reduce spot counts/SI.

• Biological variability: Cellular assays naturally vary; trends over time are often more informative than a single value.

---

Practical follow-up algorithm

1. Start with symptoms + EBV EliSpot (lytic) result.

2. If >3 SI and symptoms fit: add EBV DNA PCR, serology panel, and basic labs (CBC, LFTs).

3. If 2–3 SI and uncertain: repeat in 4–6 weeks and pair with serology ± PCR.

4. If 0–1 SI but suspicion remains high: order serology and consider PCR; reassess alternative diagnoses.

5. Use trends (clinical + lab) to guide management rather than any single test.

---

Frequently asked questions

Is a high SI dangerous by itself?
Not necessarily. It means your T-cells are reacting strongly to EBV lytic antigens. Whether that’s harmful depends on your symptoms, exam, and other labs.

Can I be positive here but have negative antibodies?
Yes. Cellular and humoral immunity don’t always move together, especially at different time points of infection or recovery.

Should I treat based on this test alone?
No. Management decisions should integrate clinical picture + serology + (when indicated) PCR + routine labs.

How soon can I re-test?
For most clinical questions, 4–6 weeks is a sensible interval to understand directionality.

---

Reporting notes & ranges

• Reference intervals (ArminLabs): 0–1 negative; 2–3 weak positive; >3 positive (SI).

• Suggested color mapping for clarity:

  • Negative: #0072B2

  • Weak positive: #E69F00

  • Positive: #D55E00
    (Choose the dark-mode equivalents if your report supports dark themes.)

---

Key limitations

• Does not quantify virus (no viral load).

• Not a stand-alone diagnostic for “chronic active EBV” or other complex syndromes.

• Cut-offs and performance are lab-specific; always interpret with the performing lab’s reference data and your clinical context.